Basic Medical Science Department, School of Medicine, Hashemite University, Zarqa, Jordan.
Infection Control Unit, Prince Hamza Hospital, Amman, Jordan.
Front Public Health. 2022 Sep 21;10:1008521. doi: 10.3389/fpubh.2022.1008521. eCollection 2022.
There is a need to establish the effectiveness of the coronavirus disease 2019 (COVID-19) vaccines in reducing COVID-19-related hopitalization of patients in Jordan. As the vaccination program accelerates, it is important to determine whether the vaccines' effectiveness (VE) has successfully reduced the number of acute cases admitted to hospital.
To determine the efficacy of Pfizer-BioNTech and Sinopharm COVID-19 vaccines among Jordanian patients admitted to Prince Hamza hospital, a single center case-control study was performed. The study analyzed the hospitalization rates of vaccinated ( = 536) and unvaccinated ( = 585) individuals across the 2-month period from February 6 to April 6, 2022. The cases were patients who tested positive for SARS-CoV-2 ("case-patients"), whilst the control group were hospital patients who did not test positive for SARS-CoV-2 ("control-patients").
This study found that among 1,121 total participants (561 cases and 560 control), the overall vaccine effectiveness (VE) among the participants was 84% (95% Cl 79-88%). VE was higher in females (88%, 95% Cl 84-93%) than in males (77%, 95% Cl 67-84%) ( < 0.001), and it was highest in those between the ages of 18 and 28-years-old (95%, 95% CI 86-98%). For patients with pre-existing conditions, including chronic heart disease, chronic lung disease, and diabetes, VE was higher compared to patients with no comorbidities, though the difference was not statistically significant. Finally, in comparing all vaccinated participants, VE was higher for those who received the Pfizer vaccine (VE = 92%, 95% CI 88-94%) (OR 0.08, 95% CI 0.06-0.12) than for those who received the Sinopharm vaccine (VE = 67%, 95% CI 52-78%) (OR 0.33, 95% CI 0.22-0.48); ( = 0.011).
Overall, Pfizer and Sinopharm vaccines were found to be effective in limiting hospitalizations for acute cases of coronavirus among Jordanian adult's patient's cohort between February 6 and April 6, 2022, especially among patients with comorbidities.
需要确定 2019 年冠状病毒病（COVID-19）疫苗在减少约旦 COVID-19 相关住院患者方面的有效性。随着疫苗接种计划的加速，确定疫苗的有效性（VE）是否成功降低了因急性病例而住院的人数非常重要。
为了确定辉瑞-生物科技和科兴 COVID-19 疫苗在约旦接受哈马王子医院治疗的患者中的效果，进行了一项单中心病例对照研究。该研究分析了 2022 年 2 月 6 日至 4 月 6 日两个月期间接种疫苗（=536）和未接种疫苗（=585）个体的住院率。病例为 SARS-CoV-2 检测呈阳性的患者（“病例患者”），而对照组为 SARS-CoV-2 检测呈阴性的住院患者（“对照患者”）。
本研究发现，在 1121 名总参与者（561 例病例和 560 例对照）中，参与者的总体疫苗有效性（VE）为 84%（95%Cl79-88%）。女性（88%，95%Cl84-93%）的 VE 高于男性（77%，95%Cl67-84%）（<0.001），18-28 岁年龄组的 VE 最高（95%，95%CI86-98%）。对于患有慢性心脏病、慢性肺病和糖尿病等既往疾病的患者，与无合并症的患者相比，VE 更高，但差异无统计学意义。最后，在比较所有接种疫苗的参与者时，接受辉瑞疫苗接种的 VE 更高（VE=92%，95%CI88-94%）（OR0.08，95%CI0.06-0.12），而接受科兴疫苗接种的 VE 较低（VE=67%，95%CI52-78%）（OR0.33，95%CI0.22-0.48）；（=0.011）。
总体而言，辉瑞和科兴疫苗在 2022 年 2 月 6 日至 4 月 6 日期间限制了约旦成年患者队列中冠状病毒急性病例的住院，尤其是在合并症患者中。
